

NOTICE

NOTICE is hereby given that the Sixth (6th) Annual General Meeting of the Members of Assam Cancer Care Foundation will be held, at shorter notice, at the Board Room, Business Centre of Vivanta by Taj, Guwahati on Saturday, the 30th day of September, 2023 at 6:00 pm., to transact the following business:

ORDINARY BUSINESS:

1. To consider, approve and adopt the Audited Financial Statements of the Company comprising the Statements of Income and Expenditure and Cash Flow for the financial year ended on March 31, 2023, and the Balance Sheet as that date, together with the Reports of the Board of Directors and Auditors thereon.
2. To re-appoint M/s Deloitte, Haskins and Sells LLP as Statutory Auditors of the Company for a period of 5 years and pass the following resolution(s) with or without modification, if any:

"RESOLVED THAT pursuant to the provisions of Section 139, 142 and other applicable provisions, if any, of the Companies Act, 2013 read with Companies (Audit and Auditors) Rules, 2014, (including any statutory modifications or re-enactment thereof, for the time being in force), **M/s Deloitte, Haskins and Sells LLP, Chartered Accountants**, be and are hereby appointed as the Statutory Auditors of the Company to hold office from the conclusion of this Annual General Meeting till the conclusion of the Annual General Meeting to be held in the calendar year 2028 at a remuneration to be decided by the Board of Directors in consultation with the Auditors;

"RESOLVED FURTHER THAT the Directors of the Company be and are hereby severally authorized to take all steps necessary and incidental for implementing the aforesaid resolution including filing the form as prescribed with the Registrar of Companies."

SPECIAL BUSINESS:

3. To consider and if thought fit, to pass with or without modification(s) the following resolution as an Ordinary Resolution:

"RESOLVED THAT pursuant to the provisions of Section 161 and other applicable provisions, if any, of the Companies Act, 2013, Mr. Pattatheyl Arun (DIN: 10043845), who was appointed by the Board of Directors as Additional Director on 07/02/2023 and who holds office up to the date of this Annual General Meeting, be and is hereby appointed as a Director of the Company."

4. To consider and if thought fit, to pass with or without modification(s) the following resolution as an Ordinary Resolution:

"RESOLVED THAT pursuant to the provisions of Section 161 and other applicable provisions, if any, of the Companies Act, 2013, Mr. Siddharth Sharma (**DIN: 10046852**), who was appointed by the Board of Directors as Additional Director on 08/03/2023 and who holds office up to the date of this Annual General Meeting, be and is hereby appointed as a Director of the Company."

**By the order of the Board
For Assam Cancer Care Foundation**



**Dr Siddharth Singh
(Director)**

DIN: 08251430

**Date: 30th September 2023
Place : Guwahati**

NOTES:

1. A member entitled to attend and vote at the Annual General Meeting (the "Meeting") is entitled to appoint a proxy to attend and vote on a poll instead of himself/herself and the proxy shall be a member of the Company.
2. The documents referred to in the Notice and Explanatory Statement, will be available for inspection by the members at the Registered office of the Company during business hours between 09:30 A.M. to 05:30 P.M. (except Saturday and Sunday) up to the date of the Annual General Meeting and will also be available during the Annual General Meeting.

EXPLANATORY STATEMENT PURSUANT TO SECTION 102 OF THE COMPANIES ACT, 2013:

ITEM NO 3. SPECIAL BUSINESS

The Board of Directors of the Company had appointed Mr. Pattatheyil Arun as Additional Director of the Company on 07/02/2023. His term of appointment expires at the ensuing AGM of the Company.

As it is in the best interests of the Company to have Mr. Pattatheyil Arun continue as a Director, the Board has recommended his appointment as Director by the Members.

None of the Directors of the Company other than the appointee are deemed to be interested or concerned in this resolution.

ITEM NO 4. SPECIAL BUSINESS

The Board of Directors of the Company had appointed Mr. Siddharth Sharma as Additional Director of the Company on 08/03/2023. His term of appointment expires at the ensuing AGM of the Company.

As it is in the best interests of the Company to have Mr. Siddharth Sharma continue as a Director, the Board has recommended his appointment as Director by the Members.

None of the Directors of the Company other than the appointee are deemed to be interested or concerned in this resolution.

**By order of the Board,
For Assam Cancer Care Foundation**



**Dr Siddharth Singh
(Director)
DIN: 08251430**

**Date: 30th September 2023
Place: Guwahati**

DIRECTORS' REPORT

To,
The Members,
ASSAM CANCER CARE FOUNDATION

The Directors are pleased to present the 6th Annual Report of **Assam Cancer Care Foundation** on the operations of the Company for the financial year ended on 31st March 2023 together with the Audited Financial Statements along with the Report of the Auditors thereon.

1. OPERATIONAL HIGHLIGHTS:

Assam Cancer Care Foundation ("ACCF" or "the Company") was incorporated as a not-for-profit company under Section 8 of the Companies Act, 2013 in December 2017 to set up a network of cancer care hospitals in the State of Assam. In the 1st Phase, setting up of ten cancer care hospitals was undertaken and in the 2nd Phase, seven more hospitals will be set up.

On 28th April 2022, Shri Narendra Modi, Hon'ble Prime Minister of India, in the presence of Dr. Himanta Biswa Sarma, Hon'ble Chief Minister of Assam, Shri Ratan Tata, Chairman, Tata Trusts and other dignitaries, inaugurated seven cancer care hospitals of ACCF located at Dibrugarh, Barpeta, Tezpur, Lakhimpur, Jorhat, Kokrajhar and Darrang. At the same event, foundation stones were also laid for seven more cancer hospitals of Phase-2 at Dhubri, Nalbari, Goalpara, Nagaon, Sivasagar, Tinsukia and Golaghat.

The construction of the remaining three hospitals of Phase-1 at State Cancer Institute (SCI) Guwahati, Silchar and Diphu are at various stages of completion with SCI and Silchar likely to start operations by January 2024 and December 2023 respectively and Diphu likely to be completed by end of 2024.

The L2 level hospitals (Dibrugarh and Barpeta) provide Radiation therapy, Surgical Oncology, Chemotherapy, Palliative Care services, Critical Care, Blood Centre, Diagnostic facilities including MRI, PET-CT, CT-Scan, Digital X-Ray, Mammography, high- end USG in radiology and advanced Laboratories. Dibrugarh Cancer Centre has also received NABH accreditation effective from 27th June 2023.

The L3 level hospitals (Tezpur, Jorhat, Lakhimpur, Kokrajhar and Darrang) provide Radiation therapy, Chemotherapy, Palliative Care services, Diagnostic facilities including MRI, CT-Scan, Digital X-Ray, Mammography, high- end USG in radiology and basic Laboratory facilities.

ACCF hospitals are empaneled under AAA/PMJAY/CMJAY schemes for cashless treatment of beneficiaries. In addition, ACCF hospitals are empaneled with ECHS, CGHS, 6 PSUs (NF Railways, NRL, BCPL, APPL, OIL, CIL) and 14 TPA/Insurance providers. Three hospitals at Barpeta, Dibrugarh, Tezpur, and the Day Care Centre at Diphu are also empaneled under ESIC.

ACCF is actively collaborating with the National Health Mission to enhance cancer screening across eight districts of Kokrajhar, Barpeta, Darrang, Diphu, Silchar, Jorhat, Dibrugarh, and Lakhimpur since 2019-20. In addition, ACCF is operating four screening kiosks located in Medical Colleges at Silchar, Barpeta, Dibrugarh, and Diphu. These kiosks are located at accessible locations where individuals can undergo screenings for oral, breast, and cervical cancers.

The patient services data for the period April 2022 till March 2023 is given in the table below:

Patient and Service Statistics (Apr2022 to Mar2023)													
Hospital	OPD	Total New patients	IPD	Major Surgery	Chemo Sessions	Radiation Count	Lab Test	CT-scan	X Ray	Mammography	MRI	PET-CT	USG
Dibrugarh	18515	4769	622	48	3255	767	29266	1573	914	72	1688	190	350
Barpeta	12733	2465	243	NA	3593	464	27637	2031	419	56	327	0	142
Jorhat	8214	2132	NA		1988	237	9047	1075	388	81	578	0	0
Tezpur	6826	1560			1956	180	7043	680	114	118	193	0	128
Lakhimpur	7117	2237			599	153	4139	417	120	69	1278	0	30
Kokrajhar	4805	1083			584	57	4296	271	150	52	485	0	0
Darrang	3684	1591			431	59	2911	337	146	16	481	0	111
Total	61894	15837	865	48	12406	1917	84339	6384	2251	464	5030	190	761

2. FINANCIAL RESULTS:

(Rs. Lakh)

Particulars	2022 - 23	2021 - 22
Grant Income	16,307.40	3,416.54
Other Income	58.24	23.21
Income from treatment of patients	4,025.02	366.26
Total Income	20,390.66	3,806.01
Total Expenditure	20,332.43	3,782.78
Excess of Income over Expenditure	58.23	23.23

The Income from treatment of patients represents the patient treatment charges at seven hospitals located at Barpeta, Dibrugarh, Jorhat, Tezpur, Kokrajhar, North Lakhimpur, Darrang and one Day-care Center at Diphu.

3. CHANGE IN NATURE OF BUSINESS:

There is no change in the nature of business of ACCF during the financial year under report.

4. MEETINGS OF THE BOARD: -

Three Board Meetings were held during the financial year under report:

Sr. No.	Dates on which the Board Meetings were held	Total strength of the Board	No. of Directors Present
1	16 June 2022	5	3
2	27 September 2022	5	4
3	04 February 2023	4	3

Attendance of Directors at Board Meetings and Annual General Meeting: -

Names of the Directors	Attendance at the Board Meeting held on			Annual General Meeting 27-Sep-2022
	16-Jun-2022	27-Sep-2022	04-Feb-2023	
Dr. Himanta Biswa Sarma	Present	Present	Absent	Present
Mr. Keshab Mahanta	Absent	Present	Present	Present
Mr Vijay Singh	Present	Absent	Present	Absent
Mr Anurag Goel	Absent	N.A	N.A	N.A
Dr Siddharth Singh	N.A	Present	Present	Present
Mr Srinath Narasimhan	Present	Present	N.A	Present

5. DIRECTORS AND KEY MANAGERIAL PERSONNEL (KMP): -

Mr Anurag Goel, IAS ceased to be a Director of the Company with effect from 16/06/2022 and Dr Siddharth Singh, IAS, Commissioner & Secretary, Medical Education and Research Department, joined the Board as Government of Assam nominee on 16/06/2022.

Mr Srinath Narasimhan ceased to be a Director of the Company with effect from 30/12/2022.

Dr Pattatheyl Arun, Director, Tata Medical Center, Kolkata was appointed as Additional Director of the Company with effect from 07/02/2023 and Mr Siddharth Sharma, CEO, Tata Trusts was appointed as Additional Director of the Company with effect from 08/03/2023.

The details of the Directors and Key Managerial Personnel of the Company as on 31/03/2023 are as follows:

SL No.	Name of Directors/KMP	Designation	Date of appointment
1.	Dr Himanta Biswa Sarma, Hon'ble Chief Minister, Assam	Chairman & Nominee Director	05/05/2018
2.	Sri Keshab Mahanta, Hon'ble Health Minister, Assam	Nominee Director	30/11/2021
3.	Sri Vijay Singh, Vice Chairman, Tata Trusts	Director	08/05/2019
4.	Dr Siddharth Singh, IAS, Commissioner and Secretary, Medical Education and Research Department, Govt of Assam	Nominee Director	16/06/2022
5.	Mr Siddharth Sharma, CEO, Tata Trusts	Additional Director	08/03/2023
6.	Dr Pattatheyil Arun, Director, TMCH	Additional Director	07/02/2023
7.	Ms Nelbymol Nelson#	Company Secretary	12/03/2020

Appointment terminated on 15th September 2023.

6. DETAILS OF FRAUD REPORTED BY AUDITOR: -

The statutory auditors of the Company have not reported any fraud on the Company by its officers or employees, the details of which are required to be mentioned in the Board's Report pursuant to section 143(12) of the Act,.

7. AUDITORS:-

M/s. Deloitte Haskins & Sells LLP Chartered Accountants (Firm Registration No. 117366W/W-1000018), were appointed as the Statutory Auditors of the Company to hold office for a period of 5 consecutive years till conclusion of the 6th Annual General Meeting (AGM) in the year 2023. M/s Deloitte Haskins and Sells LLP, being eligible, have offered themselves for re-appointment. Accordingly, in terms of section 139 of the Act, the Board recommends the re-appointment of M/s Deloitte Haskins and Sells LLP for a second term of five consecutive years to hold office from conclusion of the 6th AGM till the conclusion of 11th AGM of the Company to be held in the year 2028.

8. AUDITORS' REPORT:

The Auditors' Report for the financial year 2022-2023 does not contain any qualification, reservation, or adverse remarks. Notes to Accounts and Auditors' remarks in their report are self-explanatory and do not require any further comments.

9. CONTRACT AND ARRANGEMENTS WITH RELATED PARTIES: -

There were no related party transactions entered into during the year ended on 31st March, 2023.

10. DEPOSITS:

During the year under review, the Company neither accepted nor renewed any deposits falling within the ambit of Section 73 of the Companies Act, 2013 and the Companies (Acceptance of Deposits) Rules, 2014.

11. PARTICULARS OF INVESTMENTS, LOANS, GUARANTEES UNDER SECTION 186 OF THE COMPANIES ACT, 2013:

During the year under review, the Company did not give any loans, guarantees or make any investment covered under the provisions of Section 186 of the Companies Act, 2013.

12. TRANSFER TO RESERVES:

No amount was transferred to Reserves during the year ended on 31st March, 2023.

13. MATERIAL CHANGES AND COMMITMENTS, AFFECTING THE FINANCIAL POSITION OF THE COMPANY WHICH HAVE OCCURRED BETWEEN THE END OF THE FINANCIAL YEAR OF THE COMPANY TO WHICH THE FINANCIAL STATEMENTS RELATE AND THE DATE OF THE REPORT:

No material changes and commitments affecting the financial position of the Company have occurred between the end of the financial year and the date of this report.

14. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS AND OUTGO: -

The details pertaining to Rule 8 of Companies (Accounts) Rules, 2014 relating to conservation of energy, technology absorption and foreign exchange earnings and outgo is attached hereto as Annexure I.

15. STATEMENT RELATING TO DEVELOPMENT AND IMPLEMENTATION OF RISK MANAGEMENT POLICY OF THE COMPANY: -

The management has drawn up a Risk Management Policy which has been approved by the Board and adopted.

16. ANNUAL RETURN

Pursuant to Section 92(3) of the Companies Act, 2013, the Annual Return for the financial year 2022-2023 is available on the website of the Company at www.assamcancercarefoundation.org

17. CORPORATE SOCIAL RESPONSIBILITY (CSR):-

The provisions of Section 135(1) of the Companies Act, 2013 are not applicable to the Company for the year under review.

18. SUBSIDIARY AND ASSOCIATE COMPANIES: -

The Company does not have any Subsidiary/Associate/JV Company.

19. DETAILS OF SIGNIFICANT MATERIAL ORDERS PASSED BY THE REGULATORS / COURTS / TRIBUNAL IMPACTING THE GOING CONCERN STATUS AND COMPANY'S OPERATIONS IN FUTURE: -

There are no significant material or other orders passed by the Regulators / Courts / Tribunal which would impact the going concern status of the Company and its future operations. Hence, there is no disclosure to be made pursuant to Rule 8 (5) (vii) of Companies (Accounts) Rules, 2014.

20. SEXUAL HARRASSMENT OF WOMEN AT THE WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013: -

A policy on Prevention, Prohibition and Redressal of Sexual Harassment has been adopted by the Company and notified to the employees. The Company has constituted an Internal Committee as required under the Act for the Corporate Office and all the Units/Hospitals.

No complaints have been filed with the Internal Committee during the year under review. Two workshops on creating awareness on Prevention of Sexual Harassment were conducted for employees and IC members during the year under report.

21. DETAILS IN RESPECT OF ADEQUACY OF INTERNAL FINANCIAL CONTROLS WITH REFERENCE TO THE FINANCIAL STATEMENTS PURSUANT TO RULE 8 (5) (VIII) OF COMPANIES (ACCOUNTS) RULES, 2014:

The Company has adequate internal financial controls with reference to its financial statements, commensurate with the size and nature of its operations.

22. APPLICATION MADE OR PROCEEDINGS PENDING UNDER THE INSOLVENCY AND BANKRUPTCY CODE, 2016:

During the year under review, no application was made under the Insolvency and Bankruptcy Code, 2016 ("IBC 2016") by the Company. No proceedings are pending under IBC 2016 against the Company.

23. PARTICULARS OF VALUATION DONE AT THE TIME OF ONE-TIME SETTLEMENT AND VALUATION DONE WHILE TAKING LOAN FROM THE BANKS OR FINANCIAL INSTITUTIONS:

During the year under review, there were no instances of any one-time settlement of loans taken from Banks or Financial Institutions.

24. DIRECTORS' RESPONSIBILITY STATEMENT: -

Pursuant to the requirement under Section 134 (3) (c) of the Companies Act, 2013 (the "Act") with respect to Directors' Responsibility Statement, it is hereby confirmed that:

- (a) in the preparation of the annual accounts for the financial year ended on 31st March, 2023, the applicable accounting standards have been followed along with proper explanation relating to material departures;
- (b) the Directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company as at 31st March, 2023 and of the excess of income over expenditure of the Company for the financial year ended on that date;
- (c) the Directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Act, for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
- (d) the Directors have prepared the annual accounts on a 'going concern' basis; and
- (e) the Directors have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems are adequate and operating effectively.

25. ACKNOWLEDGMENT:

The Board wishes to place on record its appreciation and gratitude for the support and support received from the Government of Assam and all those with whom the Company has had dealings and the employees.

For and on behalf of the Board



Dr. Himanta Biswa Sarma
Chairman
(DIN-08124634)



Dr. Pattatheyl Arun
Director
(DIN: 10043845)

Place: Guwahati
Date: 30th September 2023.

Annexure I to the Directors' Report

Information pursuant to Section 134 of the Companies Act, 2013 read with Rule 8 of the Companies (Accounts) Rules, 2014 and forming part of the Directors' Report for the year ended on 31st March, 2023.

A. CONSERVATION OF ENERGY:

i. Energy Conservation measures taken:

ACCF is taking proactive steps for saving energy. While adopting the design for electrical systems for the upcoming hospitals, ACCF has selected variable frequency drives for all services like HVAC, water, fire and chiller pumps etc. These systems have distinct advantages of saving of energy by upto 67% reinforcing ACCF's commitment towards clean environment by reduction of CO₂.

Further, LED lights are being used in all the hospitals, which results in saving of around 50% in lighting loads. The project is also using the Hybrid power factor control panels to control reactive power as well as Total Harmonic Distortion (THD).

ii. Capital investments, if any; on energy conservation equipment

As the work is being executed through a design and build contract, no additional investment is required for implementing the conservation measures as these were included in the Design Basis Report (DBR) of the projects.

iii. Alternate sources of energy, if any utilized by the Company

The hospitals have provision for usage of solar power for 50% hot water requirements.

iv. Impact of measures at (i), (ii) & (iii) above for reduction of energy consumption and consequent impact on cost of production of goods:

It is expected that the measures taken will provide reduction in the annual energy consumption and cost.

B. TECHNOLOGY ABSORPTION

i. Efforts made in technology absorption:

Assam falls under Seismic Zone V, which is the most seismic active zone. ACCF has been in the forefront of adopting new technology for the projects it has undertaken. For all the hospital buildings, it has gone for adoption of National Disaster Management Authority (NDMA) guidelines compliant building using Base Isolation technology. Under this, the buildings are

designed to take double of the horizontal force compared to conventional earthquake resistant structures (as per IS 4326, 1993). The adoption has the following identified benefits:

- a) The beam-column structural frame sizing has come down providing better coordination of services in the hospital buildings
- b) The buildings are highly resistant to collapse in case of any disaster that could lead to any loss of life. The hospitals can continue to function and provide services, while the building can serve as a critical community facility when it is most needed;
- c) It is designed, with contingency plans in place and health workforce will be trained to keep the network operational

C. FOREIGN EXCHANGE EARNINGS AND OUTGO

i. Activities relating to Export; initiatives taken to increase exports; development of new export markets for products and export plans:

The Company is not engaged in any export activities.

ii. Total foreign exchange used and earned:

- **Foreign Exchange Earned – NIL**
- **Foreign Exchange Spent – 194.08 Lakhs.**

INDEPENDENT AUDITOR'S REPORT

To,
The Members of Assam Cancer Care Foundation
Report on the Audit of the Financial Statements

Opinion

We have audited the accompanying financial statements of Assam Cancer Care Foundation ("the Company"), which comprise the Balance Sheet as at 31st March, 2023, and the Statement of Income and Expenditure, the Cash Flow Statement for the year then ended, and a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the Accounting Standards prescribed under section 133 of the Act read with the Companies (Accounting Standards) Rules, 2006, as amended ("Accounting Standards") and other accounting principles generally accepted in India, of the state of affairs of the Company as at 31st March, 2023, and its excess of income over expenditure and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit of the financial statements in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibility for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules made thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion on the financial statements.

Information Other than the Financial Statements and Auditor's Report Thereon

- The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Director's report but does not include the financial statements and our auditor's report thereon.
- Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

- In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements, or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.
- If based on the work we have performed on the other information that we obtained prior to the date of this auditor's report, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the Accounting Standards and other accounting principles generally accepted in India. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Company's Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibility for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material



misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal financial control relevant to the audit in order to design audit procedures that are appropriate in the circumstances but not for the purpose of expressing an opinion on the effectiveness of company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Report on Other Legal and Regulatory Requirements

1. As required by Section 143(3) of the Act, based on our audit we report that:
 - a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.




- c) The Balance Sheet, the Statement of Income & Expenditure and the Cash Flow Statement dealt with by this Report are in agreement with the relevant books of account.
- d) In our opinion, the aforesaid financial statements comply with the Accounting Standards specified under Section 133 of the Act.
- e) On the basis of the written representations received from the directors as on 31st March, 2023 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2023 from being appointed as a director in terms of Section 164(2) of the Act.
- f) Reporting on the adequacy of Internal Financial Controls with reference to financial statements of the Company and the operating effectiveness of such controls, under section 143(3)(i) of the Act is not applicable in view of the exemption available to the Company in terms of the notification no. G.S.R. 583(E) dated 13th June, 2017 issued by the Ministry of Corporate Affairs, Government of India, read with general circular No. 08/2017 dated 25th July, 2017.
- g) In our opinion and to the best of our information and according to the explanations given to us, the Company being a private company, section 197 of the Act related to the managerial remuneration is not applicable.
- h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, as amended in our opinion and to the best of our information and according to the explanations given to us:
 - i. The Company does not have any pending litigations which would impact its financial position.
 - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
 - iii. There were no amount which were required to be transferred to Investor Education and Protection fund by the company.
 - iv. (a) The Management has represented that, to the best of its knowledge and belief, other than as disclosed in the notes to the financial statements no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
 - (b) The Management has represented, that, to the best of its knowledge and belief, other than as disclosed in the notes to the financial statements, no funds have been received by the Company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall, directly or indirectly, lend or invest in other



persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

- (c) Based on the audit procedures performed that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (a) and (b) above, contain any material misstatement.
 - v. The company is not permitted to declare the dividends being the section 8 company.
 - vi. Proviso to Rule 3(1) of the Companies (Accounts) Rules, 2014 for maintaining books of account using accounting software which has a feature of recording audit trail (edit log) facility is applicable to the Company w.e.f. 1st April, 2023, and accordingly, reporting under Rule 11(g) of Companies (Audit and Auditors) Rules, 2014 is not applicable for the financial year ended 31st March, 2023.
2. The Companies (Auditor's Report) Order, 2020 ("the Order") issued by the Central Government in terms of Section 143(11) of the Act, since the Order is not applicable to the company, being a company licensed to operate under section 8 of the companies Act, as specified in paragraph 1(2)(iii) of the Order.

For Deloitte Haskins & Sells LLP
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)



Joc Pretto
(Partner)
(Membership No. 77491)
(UDIN : 23077491BGXCZK8159)

Place: Mumbai
Date: 30th September, 2023

ACCF copy.

Assam Cancer Care Foundation
Company limited by guarantee and not having share capital
Balance Sheet as at March 31, 2023

Amount in ₹ Lacs

Particulars	Note #	As at March 31, 2023	As at March 31, 2022
I EQUITY AND LIABILITIES			
1 Shareholders' funds			
a) Share Capital	3	-	-
b) Reserves and Surplus	4	99.06	40.83
2 Liabilities			
Non-Current Liabilities			
a) Other Long Term Liabilities	5	1,54,679.26	1,21,716.08
b) Long Term Provisions	6	94.22	93.38
Current Liabilities			
a) Trade Payables	7		
ai) Total Outstanding dues to Micro Enterprises and Small Enterprises		66.81	16.12
aii) Total Outstanding dues of Creditors Other than Micro Enterprises and Small Enterprises		658.67	229.99
b) Other Liabilities	8	11,582.96	16,757.41
c) Short Term Provisions	9	27.64	9.47
Total		1,67,208.62	1,38,863.28
II Assets			
1 Non-Current Assets			
a) Property, Plant and Equipment and Intangible assets	10		
i) Property, Plant and Equipment	10A	1,01,376.71	3,566.93
ii) Intangible assets	10B	75.74	52.04
iii) Assets Under Construction	10C	42,965.37	1,07,008.46
b) Long Term Loans and Advances	11	298.15	58.57
c) Other Non-Current Assets	12	3,295.19	158.81
2 Current Assets			
a) Cash and Cash Equivalents	13	15,651.78	22,787.58
b) Trade Receivable	14	285.24	121.03
c) Short Term Loans and Advances	15	2,875.83	4,829.51
d) Other Current Assets	16	384.61	280.35
Total		1,67,208.62	1,38,863.28

Notes to and forming part of the financial statements

1 - 45

In terms of our report attached
For Deloitte Haskins & Sells LLP
Chartered Accountants



Joe Pretto
Partner

For and on behalf of Board of Directors
Assam Cancer Care Foundation
CIN:- U74999AS2017NPL018256



Himanta Biswa Sarma
Director
DIN: 08124634

Pattathayil Arun
Director
DIN: 10043845

Date: September 30, 2023
Place: Mumbai

Date: September 30, 2023
Place: Guwahati



Assam Cancer Care Foundation
Company limited by guarantee and not having share capital
Statement of Income and Expenditure for the year ended on March 31, 2023

Amount in ₹ Lacs

Particulars	Note #	Year Ended on March 31, 2023	Year Ended on March 31, 2022
1 INCOME			
a) Grants income	17	16,307.40	3,416.54
b) Other income	18	58.24	23.21
c) Income from treatment of patient charitable object		4,025.02	366.26
Total Income		20,390.66	3,806.01
2 EXPENDITURE			
a) Employee Benefit Expenses	19	790.10	580.80
b) Project Expenses	20	151.36	68.68
c) Expenditure towards charitable objects	21	7,086.56	2,108.73
d) Depreciation and Amortizations	10	11,853.49	692.05
e) Establishment Expenses	22	450.92	332.53
Total Expenditure		20,332.43	3,782.78
3 EXCESS OF INCOME OVER EXPENDITURE (1-2)		58.23	23.23

Notes to and forming part of the financial statements

1 - 45

In terms of our report attached
For Deloitte Haskins & Sells LLP
Chartered Accountants



Joe Pretto
Partner

For and on behalf of Board of Directors
Assam Cancer Care Foundation
CIN:- U74999AS2017NPL018256



Himanta Biswa Sarma
Director
DIN: 08124634



Pattatheyil Arun
Director
DIN: 10043845

Date: September 30, 2023
Place: Mumbai

Date: September 30, 2023
Place: Guwahati



Assam Cancer Care Foundation
Company limited by guarantee and not having share capital
Cash Flow Statement for the year ended March 31, 2023

Amount in ₹ Lacs

Particulars	Year Ended on March 31, 2023	Year Ended on March 31, 2022
A Cash flow from operating activities		
Excess of Income over Expenditure	58.23	23.23
Adjustments for non-cash items		
a) Depreciation and amortization	11,853.49	692.04
b) Surplus on disposal of assets	(0.04)	(0.60)
c) Donated asset reserve release	(3,444.15)	(16.35)
d) Asset written off during the year	4.35	-
e) Foreign exchange gain/(loss)	19.02	-
Operating Cash Flow Before Working Capital Adjustments	8,490.90	698.32
Adjustments for working capital:-		
(Increase) in Long Term Loans and Advances	(239.58)	(15.32)
(Increase) in Trade receivable	(164.21)	(121.03)
(Increase) in Other Assets	(112.37)	(298.81)
Increase in Liabilities and Provisions (excluding *)	(11,282.08)	(2,633.24)
Net Cash Flow Generated From Operating Activities (A)	(3,307.34)	(2,370.08)
B Cash Flow From Investing Activity		
Sale / recovery of fixed asset	0.04	0.64
(Increase) in deposit with banks	(3,100.00)	-
Decrease in earmarked deposit with banks	565.66	3,235.34
Purchase of fixed assets and assets under constructions	(21,064.82)	(41,909.56)
Net Cash (Used) from Investing Activities (B)	(23,599.12)	(38,673.58)
C Cash Flow From Financing Activity *		
Grant for Capital Assets/Under Construction	20,336.32	50,674.69
Net Cash Flow from Financing Activities (C)	20,336.32	50,674.69
D Net (Decrease) / Increase in Cash and Cash Equivalent (A+B+C)	(6,570.14)	9,631.06
E Cash and Cash Equivalent at Beginning of the Year	22,214.92	12,583.86
F Cash and Cash Equivalent at Closing of the Year	15,644.78	22,214.92
G Net (Decrease)/Increase in Cash and Cash Equivalent	(6,570.14)	9,631.06

The Cash Flow Statement has been prepared in accordance with "Indirect Method" as set out in the Accounting Standard (AS) 3 on "Cash Flow Statements" as prescribed under section 133 of the Companies Act, 2013.

* Donor funds received for acquisition of fixed assets and asset under construction classified under Other Liabilities-Note 8

In terms of our report attached
For Deloitte Haskins & Sells LLP
Chartered Accountants



Joe Pretto
Partner

For and on behalf of Board of Directors
Assam Cancer Care Foundation
CIN:- U74999AS2017NPL018256



Himanta Biswa Sarma
Director
DIN: 08124634

Pattatheyl Arun
Director
DIN: 10043845

Date September 30, 2023
Place Mumbai

Date: September 30, 2023
Place: Guwahati



ASSAM CANCER CARE FOUNDATION

(Company limited by guarantee and not having share capital)

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

1. Corporate Information:

The Company has been established to conduct various projects and programs in connection with or relating to preventive care and medical treatment of Cancer. The Company was incorporated on December 5, 2017 limited by guarantee and not having share capital pursuant to a license under Section 8(1) of the Companies Act, 2013 granted by the Ministry of Corporate Affairs, Government of India. The CIN of the Company is U74999AS2017NPL018256. The Company has received approval under Section 12A of the Income Tax Act, 1961 valid until March 31, 2026. The Company has also obtained registration under Section 80G of the Income Tax Act, 1961 valid until March 31, 2026.

The Company would incur expenditure directly towards objects and Programs which represent initiatives/activities undertaken by the Company.

2. Significant Accounting Policies:

A. Basis of Preparation of Financial Statements:

The financial statements of the Company have been prepared and presented in accordance with the generally accepted accounting principles in India (Indian GAAP) to comply with the Accounting Standards specified under Section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014, to the extent applicable.

The financial statements are prepared under the historical cost convention on accrual basis. The Company is a small and medium sized company as defined in the General Instructions in respect of Accounting Standards specified under section 133 of the Companies Act, 2013. Accordingly, the Company has complied with the Accounting Standards as applicable to a Small and Medium sized Company.

B. Use of Estimates:

The preparation of the financial statements in conformity with Indian GAAP requires the Management to make estimates and assumptions considered in the reported amounts of assets and liabilities (including contingent liabilities) and the reported income and expenses during the period. The Management believes that the estimates used in preparation of the financial statements are prudent and reasonable. Future results could differ due to these estimates and the differences between the actual results and the estimates are recognized in the periods in which the results are known / materialize.

C. Revenue Recognition:

- a) Earmarked grants are initially credited to a liability account in the Balance Sheet and are transferred to Statement of Income and Expenditure in the year in which and to the extent to which the Company complies with the conditions attached to them.
- b) Donations are recognized as income in Statement of Income and Expenditure in the period in which the collections are received.
- c) The Company recognizes revenue from medical and healthcare services to patients, on sale of medical consumables and drugs within the hospital premises and on providing services towards patient amenities. Revenue is measured at the fair value of the consideration received or receivable. Revenue is recognized upon transfer of control of promised products or services to customers/ patients in an amount that reflects the consideration we expect to receive in exchange for those products or services. Sales and Service Income exclude Goods and Service Tax (GST) and are net of trade / volume discounts, where applicable. 'Unbilled



ASSAM CANCER CARE FOUNDATION

(Company limited by guarantee and not having share capital)

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

revenue' represents value to the extent of medical and healthcare services rendered to the patients who are undergoing treatment/ observation on the balance sheet date and is not billed as at the balance sheet date.

- d) Interest Income is recognized on time proportion basis taking into account the amount outstanding.

D. Fixed Assets:

Tangible assets are stated at acquisition cost, net of accumulated depreciation and accumulated impairment losses, if any. Cost includes purchase price, taxes and any attributable cost of bringing the assets to its working condition for its intended use.

Components of Grants utilized for meeting costs of capital assets are disclosed as 'Capital Assets Fund' as a part of 'Other Non-Current Liabilities'. Costs of such assets are capitalized. Amount equivalent to depreciation provided on such asset is released from Grant to Capital Assets to Income and Expenditure Account. Further the Capital Grants have been allocated between the Donors based on the ratio 1080: 830 except State Cancer Institute, Assam Medical College, Dibrugarh and Silchar Medical College.

Donated assets have been recognized in the books at cost of acquisition of the donor, by creating an equivalent amount of reserve. Amount equal to depreciation on such donated assets is released from the reserve to Income and Expenditure Account.

E. Depreciation/Amortization:

Depreciable amount for assets is the cost of an asset, or other amount substituted for cost, less its estimated residual value. Depreciation would be calculated on Written Down Value method, except Intangible assets, which will be on Straight Line method. Depreciation would be provided as per the useful / estimated life prescribed in Schedule II to the Companies Act, 2013.

Individual assets/group of assets costing in aggregate less than Rs 10,000 are fully depreciated in the year of acquisition.

Categories of assets and their useful life based on Schedule II to the Companies Act 2013 is below:

Assets	Estimated Useful Life
Office Equipment	5 years
Computers and data processing units –	
a) Laptops and desktops	3 years
b) Other IT peripherals	6 years
Furniture and Fixtures	10 years
Building	60 years
Plant and Machinery	15 years
Medical Equipment	
a) Electrical Machinery & other diagnostic equipment's	13 years
b) Other Equipment's	15 years
Lease hold Improvement	Over period of Lease
Motor Vehicles	8 years
Roads	10 years
Electrical Installations	10 years
Intangibles-Software	3 years



ASSAM CANCER CARE FOUNDATION

(Company limited by guarantee and not having share capital)

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

F. Impairment of assets:

In accordance with Accounting Standard 28 (AS 28) on "Impairment of assets", the carrying amounts of the Company's assets are reviewed at each balance sheet date to determine whether there is any impairment. Management periodically assesses using, external and internal sources, whether there is an indication that an asset may be impaired. An impairment occurs where the carrying value exceeds the present value of future cash flows expected to arise from the continuing use of the asset and its eventual disposal. The impairment loss to be expensed is determined as the excess of the carrying amount over the higher of the asset's net sales price or present value as determined above.

G. Provision and Contingent Liabilities:

Provisions are recognized when the Company has a present obligation as a result of a past event; it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and when a reliable estimate of the amount of the obligation can be made.

No Provision is recognized for –

Any possible obligation that arises from past events and the existence of which will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the Company; or

Any present obligation that arises from past events but is not recognized because-

- (i) It is not probable that an outflow of resources embodying economic benefits will be required to settle the obligation; or
- (ii) A reliable estimate of the amount of obligation cannot be made.

Such obligations are recorded as Contingent Liabilities. These are assessed periodically and only that part of the obligation for which an outflow of resources embodying economic benefits is probable, is provided for, except in the extremely rare circumstances where no reliable estimate can be made.

Contingent Assets are not recognized in the financial statements since this may result in the recognition of income that may never be realized.

H. Expenses towards charitable objects of the trust:

- a) All expenses are accounted for on accrual basis and provision is made for all known losses and liabilities.
- b) Programme expenses shall represent expenses towards programme which are executed by the Company.

I. Foreign Exchange Transactions:

Transactions in foreign currency are recorded at the exchange rates prevailing on the date of the transaction. Exchange differences arising on settlement of revenue transactions are recognized in the Statement of Income and Expenditure. Monetary items denominated in a foreign currency are restated using the exchange rates prevailing at the date of the Balance Sheet and the resulting net exchange difference is recognized in the Statement of Income and Expenditure.

J. Employee Benefits:

Short Term Employee Benefits

All employee benefits payable wholly within twelve months of rendering the service are classified as short-term employee benefits. Benefits such as salaries, etc., are recognized as an expense at



ASSAM CANCER CARE FOUNDATION

(Company limited by guarantee and not having share capital)

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

the undiscounted amount in the Statement of Income and Expenditure of the year in which the employee renders the related service.

Post-employment Benefit Plans

Defined Contribution Plans:

Payments made to a defined contribution plan such as Provident Fund are charged as an expense in the Statement of Income and Expenditure as they fall due. Contribution to Provident Fund is recognized as an expense in the income and expenditure account when the employees have rendered services entitling them to contributions.

Defined Benefit Plans:

The liability towards gratuity to past employees is determined using the Projected Unit Credit Method which considers each period of service as giving rise to an additional unit of benefit entitlement and measures each unit separately to build up the final obligation. Past services are recognized on a straight-line basis over the average period until the amended benefits become vested. Actuarial gain and losses are recognized immediately in the statement of Statement of Income and Expenditure as surplus or deficit. Obligation is measured at the present value of estimated future cash flows using a discounted rate that is determined by reference to market yields at the Balance Sheet date on Government Securities where the currency and terms of the Government Securities are consistent with the currency and estimate terms of the defined benefit obligations.

Other Long Term Employee Benefits:

Other Long Term Employee Benefits viz., leave encashment is recognized as an expense in the Statement of Income and Expenditure as and when it accrues. The liability is determined using the Projected Unit Credit Method, with the actuarial valuation carried out as at the Balance Sheet date. Actuarial gains and losses in respect of such benefits are charged to the Statement of Income and Expenditure.

K. Income Tax:

Income taxes have been computed using the tax effect accounting method, where taxes are accrued in the same period as the related revenue and expenses. Current tax is determined as the amount of tax payable in respect of taxable income for the year, as per provisions of the Income-tax Act, 1961.

L. Cash and Cash Equivalents:

In the Cash Flow Statement, Cash and Cash Equivalents includes cash in hand, bank balances and liquid term deposits with bank having maturity term of more than 90 days and deposits with bank having maturity term of less than 90 days.

M. Leases:

Lease arrangements where the risks and rewards incidental to ownership of an asset substantially vest with the lessor are recognize as operating leases. Lease rentals under operating lease are recognised in the Statement of Income and Expenditure on a straight-line basis over the lease term.



ASSAM CANCER CARE FOUNDATION

(Company limited by guarantee and not having share capital)

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

N. Operating cycle:

Based on the nature of activities of the Company and the normal time elapsed between acquisition of assets and their realization in cash or cash equivalents, the Company has determined its operating cycle as 12 months for the purpose of classification of its assets and liabilities as current and non-current.

O. General funds:

The company generate general funds from various projects which are unrestricted in nature, which are carried forward for use in the future period. These funds are the excess of income over expenditure during the year.



Assam Cancer Care Foundation
Company limited by guarantee and not having share capital
Notes to and forming part of Financial Statement

Note 3 Equity Share Capital

The Company is a Private Limited Company within the meaning of Section 2 (68) of the Companies Act, 2013. The Company is limited by Guarantee and does not have a share capital. The liability of each member is restricted to Rs.1,000. If upon a winding up or dissolution of the Company, there remains, after the satisfaction of all the debts and liabilities, any sum of money or property whatsoever, the same shall not be distributed amongst the members of the Company but shall be given or transferred to such other company having objects similar to the objects of this Company, subject to such conditions as the Tribunal may impose, or may be sold and the proceeds thereof credited to the Insolvency and Bankruptcy Fund (IBF).

Note 4 Reserves and Surplus

1,00,000.00

Amount in ₹ Lacs

Particulars	As at March 31, 2023	As at March 31, 2022
<u>a) Surplus of Income over Expenditure</u>		
Balance at beginning of the year	40.83	17.60
Add: Excess of Income over Expenditure for current year	58.23	23.23
Total	99.06	40.83

Note 5 Other Long Term Liabilities

Amount in ₹ Lacs

Particulars	As at March 31, 2023	As at March 31, 2022
<u>a. Grants for Capital Assets</u>		
Balance at Beginning of the Year	3,430.65	2,158.30
Add: Transfer from Earmarked Funds (Refer Note 8)	224.67	71.98
Add: Transfer from Grants for Capital Assets Under Construction	87,883.50	1,876.06
Less: Transfer to Statement of Income and Expenditure	8,409.34	675.69
Balance at Close of the Year	83,129.48	3,430.65
<u>b. Grants for Capital Assets Under Construction</u>		
Balance at Beginning of the Year	1,11,990.58	73,483.73
Add: Transfer from Earmarked Funds (Refer Note 8)	23,840.41	46,671.58
Less: Transfer to/(from) Earmarked Funds (Mobilization Advance and Long Term Security Deposit) (Refer Note 12-a & 15)	1,925.42	6,288.67
Less: Transfer to Grants for Capital Assets (Refer Note 10-c)	87,883.50	1,876.06
Balance at Close of the Year	46,022.07	1,11,990.58
<u>c. Reserve for Grant in Kind</u>		
Balance at beginning of the year	186.95	-
Add: Received during the year (Refer Note 10)	21,577.96	203.30
Less: Depreciation transferred to revenue account (Refer Note 17)	3,444.15	16.35
Balance at close of the year	18,320.76	186.95
<u>d. Capital Creditors</u>	7,206.95	6,107.90
Total	1,54,679.26	1,21,716.08

Note: Reserve against "Grant in kind" represent the written down value of assets received as donation in kind, which have been accounted for at the cost of acquisition to the donor.



Assam Cancer Care Foundation
Company limited by guarantee and not having share capital
Notes to and forming part of Financial Statement

Note 6 Long Term Provisions

Amount in ₹ Lacs		
Particulars	As at March 31, 2023	As at March 31, 2022
Provision for employee benefits:		
a) Provision for Gratuity (Refer Note 27)	36.29	74.67
b) Provision for Leave Encashment (Refer Note 27)	57.93	18.71
Total	94.22	93.38

Note 7 Trade Payables

Amount in ₹ Lacs		
Particulars	As at March 31, 2023	As at March 31, 2022
1 Total Outstanding dues of Micro Enterprises and Small Enterprises	66.81	16.12
2 Total Outstanding dues of Creditors Other than Micro Enterprises and Small Enterprises	658.67	229.99
Total	725.48	246.11

a Trade Payable Ageing schedule

Particulars	Outstanding for following period from due date of payment as on March 31, 2023					Outstanding for following period from due date of payment as on March 31, 2022				
	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
i. MSME	66.81	-	-	-	66.81	15.30	0.45	-	-	15.75
ii. Others	11.67	0.30	0.03	-	12.00	70.83	0.42	-	-	71.25
iii. Disputed dues-MSME	-	-	-	-	-	-	0.37	-	-	0.37
iv. Disputed dues-Others	-	-	-	-	-	-	-	-	-	-
Total	78.48	0.30	0.03	-	78.81	86.13	1.24	-	-	87.37
Add: Bills not due and accrued expenses	635.33	8.98	2.36	-	646.67	158.74	-	-	-	158.74
Total	713.81	9.28	2.39	-	725.48	244.87	1.24	-	-	246.11

b Disclosure required under section 22 of Micro, Small and Medium Enterprises Development Act, 2006 (the Act)

Amount in ₹ Lacs		
Particulars	As at March 31, 2023	As at March 31, 2022
Principal amount and interest due thereon remaining unpaid to any supplier at year end: -		
Principal	66.18	15.67
Interest due thereon	0.06	-
Amount of interest paid by the buyer in terms of section 16 of the Act, along with the amount of payment made to the supplier beyond the appointed date during each accounting year	-	-
Amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under the Act.	0.12	-
Amount of interest accrued and remaining unpaid at end of each accounting year	0.63	0.45
Amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues above are actually paid to the small enterprise, for the purpose of disallowance of a deductible expenditure under section 23 of the Act.	-	-

The amount due to Micro, Small and Medium Enterprise as defined in the "The Micro, Small and Medium Enterprises Development Act, 2006" has been determined to the extent such parties have been identified on the basis of the information collected by the Management.



Assam Cancer Care Foundation
Company limited by guarantee and not having share capital
Notes to and forming part of Financial Statement

Note 8 Other Liabilities

Particulars	Amount in ₹ Lacs	
	As at March 31, 2023	As at March 31, 2022
a) <u>Unspent Grant of Donor Agencies</u>		
Balance at Beginning of the Year	16,354.89	8,159.76
Add Grants received during the year (Refer Note 24)	20,336.32	50,674.69
Add Interest earned during the year (Refer Note 24)	912.98	699.83
Less Transfer to Grants for Capital Assets (Refer Note 10)	224.67	71.98
Less Transfer to Grants for Capital Assets Under Construction (Gross) (Refer Note 10)	23,840.41	46,671.58
Add Transfer to/(from) Earmarked Funds (Mobilization Advance and Long Term Security Deposit) (Refer Note 12-a & 15)	1,925.42	6,288.67
Less Transfer from Earmarked Funds for Patient Support (Refer Note 24)	7.27	-
Less Transfer to Statement of Income and Expenditure (Refer Note 17)	4,453.91	2,724.50
	11,003.35	16,354.89
b) Statutory dues	153.40	156.40
c) Retention money	256.42	91.55
d) Employee benefit payable	51.15	26.30
e) Security deposit	82.15	128.27
f) Advance from customers	36.49	-
Total	11,582.96	16,757.41

Note: The amount unutilized from Earmarked Funds represent amount received from various donors and sponsors for specific projects under taken/ to be undertaken by the company which have remained unutilized as at the Balance Sheet date.

Note 9 Short Term Provisions

Particulars	Amount in ₹ Lacs	
	As at March 31, 2023	As at March 31, 2022
<u>Provision for employee benefits:</u>		
a) Provision for Gratuity (Refer Note 27)	4.84	7.69
b) Provision For Leave Encashment (Refer Note 27)	22.80	1.78
Total	27.64	9.47

Note 11 Long Term Loans and Advances

Particulars	Amount in ₹ Lacs	
	As at March 31, 2023	As at March 31, 2022
Unsecured, considered good. To parties other than related parties Advance Income Tax (Including TDS & TCS)	298.15	58.57
Total	298.15	58.57

Note 12 Other Non-Current Assets

Particulars	Amount in ₹ Lacs	
	As at March 31, 2023	As at March 31, 2022
Unsecured, considered good.		
a) Long term Security Deposit-APDCL	180.87	152.60
b) Long term Security Deposit-Others	14.32	6.21
c) Bank deposits (original maturity of more than 12 months)	3,100.00	-
Total	3,295.19	158.81



Note 10 Property, Plant, and Equipment and Intangible Assets

Sr. No.	Particulars	Gross Block (at Cost)					Depreciation		Net Block		
		As at April 1, 2022	Adjustment	Addition during the year	Deduction / Transfer/Sale during the year	Asset Written off	As at March 31, 2023	For the year	As at March 31, 2023	As at March 31, 2022	
A. Property, Plant and Equipment											
(i) Tangible Assets purchased from Donors/Funds											
1.	Transport (and (Refer Note below)	0.05	-	-	-	-	0.05	-	-	0.05	
2.	Building	375.31	-	50,992.31	-	5.03	41,362.75	2,583.40	2,601.15	38,759.64	
3.	Medical Equipments	5,551.21	-	3,794.89	-	-	9,346.10	861.33	1,480.19	7,865.91	
4.	Paint and Machinery	12.64	1.16	11,575.96	-	-	11,589.76	1,791.04	1,793.84	9,794.92	
5.	Furniture & Fixture	41.88	-	3,007.47	-	-	3,049.35	14.84	167.81	2,931.54	
6.	Laptops & Computers *	108.09	-	1.54	-	0.12	109.51	18.36	98.70	100.84	
7.	Office Equipments	11.40	-1.16	175.15	-	-	184.39	30.78	67.88	116.51	
8.	Vehicle	11.69	-	-	-	-	11.69	1.21	10.22	10.48	
9.	Lease hold improvement	88.73	-	80.36	-	-	169.09	0.99	90.71	78.38	
10.	Boards	-	-	2,024.77	-	-	2,024.77	654.18	654.18	1,370.59	
11.	Perennial Installation & Equipment	30.25	-	10,406.46	-	-	10,436.71	2,362.31	2,371.46	8,065.25	
	Total A (i)	4,234.84	-	88,958.37	-	5.20	92,789.01	8,376.03	9,231.06	83,552.95	
	Previous Year	2,340.63	0.78	2,080.90	-	-	4,421.31	653.91	4,769.87	2,718.94	
(ii) Tangible Assets received as donation in kind from Donors											
1.	Vehicles	203.30	-	39.84	-	-	243.14	16.46	812.81	101.26	
2.	Medical Equipment	-	-	20,746.59	-	-	20,746.59	8,041.57	3,041.57	17,705.02	
3.	Medical Furniture	-	-	302.36	-	-	302.36	72.49	229.87	-	
4.	IT assets	-	-	409.18	-	-	409.18	263.63	263.63	-	
	Total - A (ii)	203.30	-	21,457.96	-	-	21,761.26	3,444.15	3,460.50	186.95	
	Previous Year	-	-	203.30	-	-	203.30	18.35	18.35	-	
Total Tangible Assets - A											
	Total Tangible Assets	4,438.14	0.78	1,09,416.33	-	5.20	1,14,050.27	11,820.18	12,691.56	83,839.90	
	Previous Year	2,340.63	-	2,084.20	-	-	4,424.83	666.26	5,097.09	2,718.94	
B Intangible Assets											
	Software license	57.82	-	94.01	-	-	151.83	30.31	38.09	52.04	
	Total Intangible Assets - B	57.82	-	94.01	-	-	151.83	30.31	38.09	52.04	
	Previous Year	-	-	57.82	-	-	57.82	5.78	5.78	-	

* Includes assets received as Grant in kind from Tata Education and Development Trust for DINC



Note 10 Property, Plant and Equipment and Intangible Assets Continued:

[illegible]

Amount in ₹ Lacs

Particulars	Amount in CNRP for a period of					Total
	Less than 1 year	1-2 years	2-3 years	3-4 years		
Projects in progress (31-Mar-23)	17,259.72	14,187.86	11,429.72	9,088.07		41,965.37
Projects in progress (31-Mar-22)	50,627.30	44,175.21	32,205.04	-		1,07,008.46
Projects temporarily suspended	-	-	-	-		-

The Company has received land allotment letters from various authorities in the State of Arizona as stated below

Slra Name	Authority	Total Cost	Lease Period	Renewable (Y/N)
Burpeta	Deputy Commissioner, Burpeta	FOC	30 Years	Yes
Obangali	Deputy Commissioner, Obangali	FOC	30 Years	Yes
Tengour	Deputy Commissioner, Tengour	FOC	30 Years	Yes
Jorhat	Deputy Commissioner, Jorhat	FOC	30 Years	Yes
Lakshampur	Deputy Commissioner, Lakshampur	FOC	30 Years	Yes
Khatrapar	11 Sec. Rudraleswari Panchayat Council	FOC	30 Years	Yes
Dumung	Deputy Commissioner, Dumung	FOC	30 Years	Yes
Sikhar	Deputy Commissioner, Sikhar	FOC	30 Years	Yes
Chelma	11 Sec. Sarthi Angulom Autonomous Council	Rs. 4.27 Cr.		N/A

c. Particulars of projects whose completion is overdue or has exceeded its cost compared to original plan (not suspended)

Particulars	To be completed in		Total
	less than 1 year	1-3 years	
Dugha	21,885.93	4,601.72	4,601.72
Mate Cement Industries, Goudanahalli	15,477.72		21,885.93
Salt lake	38,361.65		16,477.72
Grand total	4,601.72		42,965.37

d. Donated assets have been valued at its original cost of acquisition to the donor and written off over its useful life as per the policy of the company.



Assam Cancer Care Foundation
Company limited by guarantee and not having share capital
Notes to and forming part of Financial Statement

Note 13 Cash and Cash Equivalents

Amount in ₹ Lacs		
Particulars	As at March 31, 2023	As at March 31, 2022
a) Balance with scheduled banks		
In Current Account	5.97	608.38
In Savings Account (Refer Note (ii) below)	7,261.58	3,980.44
In Deposit Account (maturity less than 3 months)	-	4,583.78
In Corporate Liquid Term Deposit-State Bank of India	8,371.85	13,042.12
b) Cash on hand	5.38	0.20
c) Earmarked Deposits on lien	7.00	572.66
Total	15,651.78	22,787.58
Note:- i) Of the above, the balances that meet the definition of cash and cash equivalent as per A5-3 Cash Flow Statement is	15,644.78	22,214.92
ii) Includes amounts earmarked for gratuity	41.13	81.44

Note 14 Trade Receivable

Amount in ₹ Lacs		
Particulars	As at March 31, 2023	As at March 31, 2022
1 Unsecured considered good	285.24	121.03
Total	285.24	121.03

Trade Receivable Ageing Schedule

Amount in ₹ Lacs												
Particulars	Outstanding for following period from due date of payment as on March 31, 2023						Outstanding for following period from due date of payment as on March 31, 2022					
	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	Total	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	Total
i. Undisputed trade receivable - considered good	281.24	4.00	-	-	-	285.24	118.20	2.83	-	-	-	121.03
ii. Undisputed trade receivable - which have significant increase in credit risk	-	-	-	-	-	-	-	-	-	-	-	-
iii. Undisputed trade receivable - credit impaired	-	-	-	-	-	-	-	-	-	-	-	-
iv. Disputed trade receivable - considered good	-	-	-	-	-	-	-	-	-	-	-	-
v. Disputed trade receivable - which have significant increase in credit risk	-	-	-	-	-	-	-	-	-	-	-	-
vi. Disputed trade receivable - credit impaired	-	-	-	-	-	-	-	-	-	-	-	-
Total	281.24	4.00	-	-	-	285.24	118.20	2.83	-	-	-	121.03



Assam Cancer Care Foundation
Company limited by guarantee and not having share capital
Notes to and forming part of Financial Statement

Note 15 Short Term Loans and Advances

Particulars	Amount in ₹ Lacs	
	As at March 31, 2023	As at March 31, 2022
Unsecured, considered good.		
a) Mobilization Advance	2,875.83	4,829.51
Total	2,875.83	4,829.51

Note 16 Other Current Assets

Particulars	Amount in ₹ Lacs	
	As at March 31, 2023	As at March 31, 2022
Unsecured considered good.		
a) Interest Accrued	288.99	203.67
b) Prepaid Expenses	80.08	59.68
c) Security Deposits	4.42	5.00
d) Advance to creditors	11.12	12.00
Total	384.61	280.35



Assam Cancer Care Foundation
Company limited by guarantee and not having share capital
Notes to and forming part of Financial Statement

Note 17 Grants Income

Amount in ₹ Lacs		
Particulars	Year Ended on March 31, 2023	Year Ended on March 31, 2022
a) Transferred from Earmarked Funds (Refer Note 8)	4,453.91	2,724.50
b) Transferred from Capital Grant Funds (Refer Note 5)	8,409.34	675.69
c) Transfer from Reserve for Grant in kind (Refer Note 5)	3,444.15	16.35
Total	16,307.40	3,416.54

Note 18 Other Income

Amount in ₹ Lacs		
Particulars	Year Ended on March 31, 2023	Year Ended on March 31, 2022
a) Bid document/Processing fees	0.05	1.58
b) Interest on IT refund	3.97	2.33
c) Surplus on disposal of assets	0.04	0.60
d) Other Income	26.71	16.90
e) Interest received	27.47	1.80
Total	58.24	23.21

Note 19 Employee Benefit Expenses

Amount in ₹ Lacs		
Particulars	Year Ended on March 31, 2023	Year Ended on March 31, 2022
a) Salaries and Wages	614.88	430.10
b) Contribution to Provident Fund & Employees State Insurance	29.30	19.49
c) Contribution to Gratuity	19.72	5.15
d) Staff Welfare and Training	25.07	13.75
e) Stipend paid	0.15	0.47
f) Recruitment expenses	100.98	111.84
Total	790.10	580.80

Note 20 Project Expenses

Amount in ₹ Lacs		
Particulars	Year Ended on March 31, 2023	Year Ended on March 31, 2022
a) Travel and Conveyance	40.20	30.53
b) Power and Fuel Charges	0.56	0.42
c) Rental Charges	6.05	4.95
d) Repairs and Maintenance	1.79	11.05
e) Inauguration Expenses	86.79	0.40
f) Guest House expenses	0.36	2.16
g) Printing & Stationery	0.09	0.37
h) Security guard charges	10.27	4.16
i) Contractual Manpower Expenses	5.25	14.64
Total	151.36	



Assam Cancer Care Foundation
Company limited by guarantee and not having share capital
Notes to and forming part of Financial Statement

Note 21 Expenditure on Charitable Object of Trust

Particulars	Amount in ₹ Lacs	
	Year Ended on March 31, 2023	Year Ended on March 31, 2022
a) <u>Hospital Operating Expenses</u>		
a.i) Awareness, Screening and Events	4.11	2.56
a.ii) Cost of Medicine Purchase	852.82	-
a.iii) Patient accomodation expense	21.51	8.11
a.iv) Medical & Surgical Consumables	181.65	41.80
a.v) Office Expenses	88.95	4.58
a.vi) Hostel expense	204.24	-
a.vii) Housekeeping Services	291.77	10.25
a.viii) Power and Fuel charges	1,033.38	145.70
a.ix) Contribution to Provident Fund & Employees State Insurance	74.75	36.62
a.x) Salaries and Wages	1,672.61	808.02
a.xi) Professional fees	1,077.71	589.68
a.xii) Other Operating Expenses	77.62	-
a.xiii) Registration and Licensing	20.33	5.64
a.xiv) Repairs and Maintenance	0.68	0.17
a.xv) Staff Welfare and Training	62.58	1.79
a.xvi) Contractual Manpower Expenses	261.89	1.78
b) <u>Hospital Operating Expenses - State Cancer Institute</u>		
b.i) Housekeeping Services	95.90	88.22
b.ii) Office Expenses	2.98	1.21
b.iii) Repairs and Maintenance	1.31	0.53
b.iv) Power and Fuel charges	1.75	0.96
b.v) Contractual Manpower Expenses	69.79	56.44
c) <u>Others</u>		
c.i) Telephone & Internet Expenses	31.16	22.05
c.ii) Travel and Conveyance	143.64	76.55
c.iii) Printing & Stationery	41.68	4.96
c.iv) Advertisement	4.11	4.44
c.v) Staff Welfare and Training	15.81	5.18
c.vi) Repairs and Maintenance	42.14	7.35
c.vii) Bad debts written-off	-	8.99
c.viii) Contractual Manpower Expenses	333.96	103.96
c.ix) Office Expenses	43.48	14.82
c.x) Rental charges	13.95	4.07
c.xi) Security guard charges	309.74	24.35
c.xii) Cloud Service Expenses	4.46	23.11
c.xiii) Guest House expenses	1.87	3.86
c.xiv) Information Technology expenses	2.23	0.98
	7,086.56	2,108.73



Assam Cancer Care Foundation
Company limited by guarantee and not having share capital
Notes to and forming part of Financial Statement

Note 22 Establishment Expenses

Particulars	Amount in ₹ Lacs	
	Year Ended on March 31, 2023	Year Ended on March 31, 2022
a) Advertisement expenses	5.97	4.99
b) Rental charges	60.38	44.55
c) Guest House expenses	2.35	2.13
d) Printing & Stationery	4.90	2.94
e) Auditors remuneration (Refer note below)	10.61	10.24
f) Information Technology expenses	24.14	19.03
g) Insurance other assets	10.18	40.47
h) Telephone & Internet expenses	18.14	4.29
i) Postage & Courier charges	3.02	0.74
j) Power and Fuel Charges	12.45	12.59
k) Office expenses	22.26	20.33
l) Cloud Service Expenses	5.64	3.07
m) Professional fees	186.73	97.55
n) Travel and Conveyance	37.75	43.59
o) Repairs and Maintenance	2.42	0.73
p) Foreign exchange loss/(Gain)	19.02	1.29
q) Security guard charges	0.42	-
r) Contractual Manpower Expenses	24.54	24.00
Total	450.92	332.53

Note:- Auditor's remuneration (inclusive of GST)

	Amount in ₹ Lacs	
	Year Ended on March 31, 2023	Year Ended on March 31, 2022
a) For Statutory Audit Fees	9.58	9.44
b) Out of Pocket Expenses	0.44	0.21
c) Certification matters	0.59	0.59
Total	10.61	10.24



Assam Cancer Care Foundation
Company limited by guarantee and not having share capital
Notes to and forming part of Financial Statement

Note 23 Ratio Analysis

Ratio	Numerator	Denominator	FY 2022-2023	FY 2021-2022	Variance	%	Reason for change (Refer Note below)
(a) Current ratio	Current Asset	Current Liabilities	1.56	1.65	0.09	5%	Refer below Note 1
(b) Debt-equity ratio	Not applicable						Refer below Note 2
(c) Debt service coverage ratio	Not applicable						Refer below Note 2
(d) Return on equity ratio	Not applicable						Refer below Note 3
(e) Inventory turnover ratio	Not applicable						Refer below Note 4
(f) Trade receivables turnover ratio	Not applicable						Refer below Note 5
(g) Trade payables turnover ratio	Not applicable						Refer below Note 5
(h) Net capital turnover ratio	Not applicable						Refer below Note 5
(i) Net profit ratio	Not applicable						Refer below Note 5
(j) Return on capital employed	Not applicable						Refer below Note 5
(k) Return on investment	Not applicable						Refer below Note 6

Notes:

- 1) Explanation shall be provided for any change in the ratio by more than 25% as compared to the ratio of preceding year.
- 2) The company does not have any debt taken during the year or outstanding of earlier year. Thus this ratio is not applicable.
- 3) The entity is section 8 company with limited guarantee. There is no equity share capital authorized/issued. Thus this ratio is not applicable.
- 4) We are providing services and there is no inventory. Hence this ratio is not applicable.
- 5) The entity is section 8 company i.e. a not for profit organization. Thus there is no profit motive involved thus, this ratio is not applicable.
- 6) The company does not have investment. Thus this ratio is not applicable.



Assam Cancer Care Foundation
Company limited by guarantee and not having share capital
Notes to and forming part of Financial Statement

Note: 24 Unspent Grant of Donor Agencies

Sr #	Name of the donor	Purpose	Opening Balance as on April 1, 2022	Received / (-) Refund during the year	Interest Earned during year	Total balance	Utilised-Purchase of Fixed Assets	Transfer to Income / Expenditure	Utilised for Patient support	Total Utilised	Closing Balance as on March 31, 2023
1	D Mart Foundation	For Cancer prevention and screening program and patient support	-	57.26	0.58	57.84	-	12.64	7.27	19.91	37.93
2	Tata Education and Development Trust	Setting-up cancer hospital in state of Assam	56.97	-	1.46	58.43	50.00	-	-	50.00	8.43
3	Tata Education and Development Trust	Setting-up of cancer care hospital in state of Assam	2,897.36	-	145.93	3,043.29	-	-	-	-	3,043.29
4	Government of Assam	Setting-up cancer hospital in state of Assam	13,308.37	20,000.00	762.16	34,070.53	22,047.37	4,243.68	-	26,291.05	7,779.48
5	Nunialgarh Refineries Ltd	Developing Oncology services in Bargaeta	(43.26)	83.15	0.53	40.42	-	-	-	-	40.42
6	Tata Education and Development Trust (BPCL)	Setting up Cancer Hospitals in Darrang	92.29	-	1.86	94.15	42.31	-	-	42.31	51.84
7	Indusind Bank Ltd (Grant MoU 001)	For Cancer prevention and screening program in Lakhimpur, Jorhat and Kokrajhar	3.18	95.00	0.21	98.39	-	95.00	-	95.00	3.39
8	ACE (Plover)	For Cancer prevention and screening program in Diphu and Silchar	15.79	100.91	0.25	116.95	-	78.63	-	78.63	38.32
9	Tata Education and Development Trust (Corona Kavach)	For Employee insurance covering Corona	23.68	-	-	23.68	-	23.68	-	23.68	-
10	Tata Education and Development Trust (EAP)	For Employee Awareness	0.53	-	-	0.53	-	0.28	-	0.28	0.25
	Total		16,354.91	20,336.32	912.98	37,604.19	22,139.68	4,453.91	7.27	26,600.86	11,003.35
	Previous Year		8,159.77	50,674.69	699.83	59,534.29	40,454.88	2,724.50	-	43,179.38	16,354.91

Note: The amount utilised from Earmarked funds represent amounts received from various donors and sponsors for specific projects undertaken / to be undertaken by the Company, which have remained unutilised as at the Balance Sheet date.

* The debit balance in a project under earmarked fund represents expenditure in excess of receipts by use of funds of another project/donor.



Assam Cancer Care Foundation
Company Limited by Guarantee and not having share capital
Notes to and forming part of Financial Statement

Note 25 Capital Commitments

Estimated amount of contracts remaining to be executed on capital account, net of advance, and not provided for Rs. 18,995.20 Lacs (Previous year Rs. 30,185.35 Lacs)

Note 26 Contingent Liabilities

Claims against company not acknowledged as debt Rs Nil (Previous year Rs Nil)

Note 27 Disclosure in respect of employee benefits under Accounting Standard (AS) - 15 (Revised) "Employee Benefits" prescribed under section Companies (Accounting Standards) Rules, 2006.

a) Defined Contribution Plan

Both the employees and the Company make predetermined contribution to the Provident Fund and ESIC. Amounts recognised as expense towards employers' contribution to Provident Fund and ESIC amounted to Rs. 94.87 Lacs (Previous Year Rs. 53.11 Lacs) and Rs. 9.18 Lacs (Previous Year Rs. 3.01 Lacs) respectively and included in note 19 and 21 to the financial statement.

b) Defined Benefit Plan

Gratuity cost amounting to Rs. 19.72 Lacs (Previous Year Rs. 4.24 Lacs).

The following disclosures are made in compliance with the Accounting Standard 15 - "Employee Benefits" based on independent actuarial valuation

Amount in ₹ Lacs

Particulars	For the year ended 31 March, 2023	For the year ended 31 March, 2022
i) Change in Present Value of Defined Benefit Obligation		
Present value of the obligation at the beginning of the year	81.44	15.40
Current Service Cost	18.55	10.16
Liability transferred in *	-	61.80
Benefit paid directly by the employer	(61.49)	-
Actuarial (Gains)/Losses on Obligations - Due to change in Financial Assumptions	(0.36)	(2.30)
Actuarial (Gains)/Losses on Obligations - Due to change in Experience	10.97	(4.61)
Actuarial (Gains)/Losses on Obligations - Due to change in Demographic assumption	(15.01)	(0.01)
Interest Cost	5.57	1.00
Present value of the obligation at the end of the year	39.67	81.44
ii) Amounts Recognised in the Balance Sheet:		
Present value of Benefit Obligation at the end of the year	39.67	81.44
Fair value of Plan	-	-
Funded status (Surplus/(-)Deficit)	39.67	81.44
Net Obligation at the end of the year	39.67	81.44
iii) Expense Recognised in the Statement of Profit and Loss:		
Current Service Cost	18.55	10.16
Actuarial (Gains)/Losses on Obligations - Due to change in Financial Assumptions	(0.36)	(2.30)
Actuarial (Gains)/Losses on Obligations - Due to change in Experience	10.97	(4.61)
Actuarial (Gains)/Losses on Obligations - Due to change in Demographic assumption	(15.01)	(0.01)
Interest cost	5.57	1.00
Net Cost Included in Personnel Expenses	19.72	4.24
iv) Actuarial Assumptions		
i) Discount Rate	7.29%	6.84%
ii) Salary Escalation Rate	8.20%	8.00%
iii) Employee Turnover	27.14%	12.00%
iv) Mortality	Indian Assured Lives Mortality (2006-08) Ultimate	Indian Assured Lives Mortality (2006-08) Ultimate

The estimates of future salary increases, considered in actuarial valuation, take account of inflation, seniority, promotion and other relevant factors, such as supply and demand in the employment market.

* This amount represent the gratuity in respect of employees who have been transferred to the Company.



Assam Cancer Care Foundation
Company Limited by Guarantee and not having share capital
Notes to and forming part of Financial Statement

v) Experience Adjustments

Experience Adjustments (Gain) / Loss:	For the year ended 31 March, 2023	For the year ended 31 March, 2022
On Plan Liabilities	10.97	(4.61)

c.i) Defined benefit plan - Compensated absences - Unfunded

Compensated absences for the year amounting to Rs. 78.96 Lacs is recognised as expenses has been included in Note 19a and Note 21a.x under Salary & Wages. (Previous year was Rs. 5.96 Lacs)

c. ii) Actuarial assumptions for long-term compensated absences - Unfunded

Particulars	For the year ended 31 March, 2023	For the year ended 31 March, 2022
i) Discount Rate	7.29%	6.84%
ii) Salary Escalation Rate	8.20%	8.00%
iii) Rate of Employee Turnover	27.14%	12.00%

Note 28 Details of Leasing arrangements

As Lessee:-

- The Company has entered into Operating Lease arrangements for certain facilities. The tenor of lease varies from eleven months to one hundred and twenty month and may be renewed further based on mutually agreed terms, some of which are non-cancellable.
- The total lease payments recognised in the Statement of Income and Expenditure for the year is Rs. 80.31 Lacs (Previous Year Rs.53.57 Lacs).

Note 29 Tax Status of the Company

The Company is registered under Section 12AA of the Income Tax Act, 1961 which entitles it to claim an exemption from income tax, provided certain conditions laid down in the Income Tax Act, 1961 are complied with. Provision for income tax would be made only in the year in which the Company is unable to establish reasonable certainty of its ability to fulfill these conditions. The company has also taken a reregistration under section 12A as prescribed through the amendment of the Finance Act 2020. The Company has also obtained a new certificate under Section 80G of the Income Tax Act, 1961 as prescribed through the amendment of the Finance Act 2020. The registrations have been obtained for a period of five years commencing from assessment year 2022-23.

Note 30 Undisclosed Income

There are no transactions which has not been recorded in the books of account and which has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961.

Note 31 Foreign Currency Transactions

Value of imports on CIF basis in respect of Capital Goods - NIL (Previous year Rs. 999.07 Lacs)

Note 32 Segment Reporting

The company is registered as a section 8 company established to undertake various projects and programmes for treatment of cancer as primary and secondary segments. The same represents a single business segment, which operates in India and no separate segmentation or reporting is required as per the Accounting Standard 17 " Segment Reporting "

Note 33 Relationship with Struck off Companies

The company has not entered into any transactions with companies, other than those mentioned below, whose name is struck off under Section 248 of the Companies Act, 2013 or Section 560 of the Companies Act, 1956 during the year ended 31st March 2023 and 31st March 2022.

Name of struck-off company	Nature of transaction	Balance outstanding-Rs lacs	Relationship
Valentia De Force Pvt Ltd	Security guard services	Nil (Previous Year Rs Nil)	No relation

Note 34 Details of Benami Property held

No proceeding has been initiated or pending against the company for holding any benami property under the Benami Transactions (Prohibition) Act, 1985 (45 of 1988) and rules made thereunder.



Assam Cancer Care Foundation
Company Limited by Guarantee and not having share capital
Notes to and forming part of Financial Statement

Note 35 Wilful Defaulter

The company has not been declared as a wilful defaulter by any bank or financial institution or other lender.

Note 36 Registration of charges or satisfaction with Registrar of Companies

No charges for registration or satisfaction, beyond the statutory period, are pending to be registered with Registrar of Companies.

Note 37 Loans and advances

The company has not given any loans or advances in the nature of loans to promoters, directors, Key Management Personnel (KMP) and related parties as defined under the Companies Act, 2013.

Note 38 Crypto Currency or Virtual Currency

The Company has not traded or invested in Crypto Currency or Virtual Currency during the financial year.

Note 39 Compliance with number of layers of companies

There are no subsidiary companies as defined under section 2(87) of the Companies Act, 2013 and hence no disclosures are required to be made.

Note 40 Corporate Social Responsibility (CSR)

The company does not fulfill provisions of section 135 of the Companies Act, 2013 and hence no disclosure is made under CSR.

Note 41 Utilization of funds

There are no funds which have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the company to or in any other person(s) or entity (ies), including foreign entities ("Intermediaries") with the understanding, whether recorded in writing or otherwise, that the Intermediary shall lend or invest in party identified by or on behalf of the company (Ultimate Beneficiaries). The company has not received any fund from any party(s) (Funding Party) with the understanding that the company shall whether directly or indirectly lend or invest in other person or entities identified by or on behalf of the company (Ultimate Beneficiaries) or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

There are no funds which have been received by the company from any other person(s) or entity (ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the company shall directly or indirectly, lend or invest in other person or entities identified in any manner whatsoever (Ultimate Beneficiaries") by or on behalf of the Funding Party or provide any guarantee, security or the like from or on behalf of the Ultimate Beneficiaries.

Note 42 Compliance with approved Scheme(s) of Arrangements

No Scheme(s) of Arrangements has been approved by the Competent Authority in terms of section 230 to 237 of the Companies Act, 2013.

Note 43 Borrowings of funds

The company has not borrowed funds from any banks or financial institutions on the basis of security of current assets.

Note 44 Other Note

Information with regards to other matters specified in Schedule III, Division I to Companies Act, 2013 is not applicable for the year ended March 31, 2023.

Note 45 Previous Year Figures

Figures for the previous period have been regrouped / restated wherever necessary to conform to current year's presentation.

For and on behalf of Board of Directors
Assam Cancer Care Foundation


Himanta Biswa Sarma
Director
DIN: 08124634


Pattatheyl Arun
Director
DIN: 10043845



Date: September 30, 2023
Place: Guwahati

